The Centers for Disease Control and Prevention (CDC) has adopted new vaccine recommendations that expand protection for respiratory syncytial virus (RSV) and meningococcal disease, backing products ...

The new RSV recommendation calls for a single dose of vaccine for adults age 50 to 59 years who are at increased risk of ...

The expanded recommendation is good news for Moderna, Pfizer, and GSK, which all sell RSV vaccines for older adults. Moderna ...

The U.S. Centers for Disease Control and Prevention has accepted recommendations made by a panel of vaccine experts in April, ...

The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50 instead of 60 ...

In addition to the RSV vaccine vote, the committee also recommended use of a new meningococcal vaccine from GSK, a chikungunya vaccine from Bavarian Nordic, and voted to tweak a previous ...

The CDC says that studies of the real-world effectiveness of Arexvy during the 2023–2024 respiratory virus season showed the vaccine to be about 77 percent effective in preventing RSV-associated ...

The CDC says everyone 75 years and older should get the shot, if they didn’t get the vaccine last year. (Again, the first RSV vaccine was approved in May of 2023, so one RSV season has passed ...

Last year was the first year that the US had vaccines available to protect against all three major respiratory viruses — COVID-19, flu and RSV — but vaccine uptake was low for the season.

Unlike the flu and Covid-19 vaccines, the RSV vaccine is one-time dose. Older adults who received an RSV vaccine last year when they first became available do not need to get another one this year.